Authors


Anees B. Chagpar, MD

Latest:

Ongoing Clinical Trials in TNBC

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses ongoing clinical trials in the field of triple-negative breast cancer (TNBC).


Anees B. Chagpar, MD, MPH, MBA

Latest:

Dr. Chagpar on Contralateral Prophylactic Mastectomy

Anees B. Chagpar, MD, MPH, MBA, Yale Comprehensive Cancer Center, discusses contralateral prophylactic mastectomy for patients with breast cancer.



Anette Duensing, MD

Latest:

Treatment Type and Cognitive Impairment in GIST

During the 2018 Annual Meeting of the Connective Tissue Oncology Society, Anette Duensing, MD, assistant professor of pathology at University of Pittsburgh, discusses the need for further investigation into how treatment type impacts perceived cognitive function in patients with gastrointestinal stromal tumor.


Angela DeMichele, MD

Latest:

The Role of DNA Repair in Triple Negative Breast Cancer

Angela M. DeMichele, MD, professor of Medicine and Epidemiology, University of Pennsylvania, discusses the biology of triple negative breast cancer and the significant role of DNA repair.


Angela DeMichele, MD, MSCE

Latest:

Analyzing Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer

Angela DeMichele, MD, MSCE, discusses predictors of response to neoadjuvant chemotherapy in various subgroups of patients with breast cancer. Selecting characteristics of patients who will most likely benefit from this therapy is not an exact science, she adds.


Angela Dispenzieri, MD

Latest:

An Analysis of the PANORAMA 1 Trial

Angela Dispenzieri, MD, a professor of medicine in the division of hematology at the Mayo Clinic, discusses the results of the PANORAMA 1 trial: a randomized, double-blind, phase III study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.


Angeles Alvarez Secord, MD

Latest:

Data Demonstrate Efficacy of 3 PARP Inhibitors in Ovarian Cancer

Angeles Alvarez Secord, MD, discusses the key takeaways on the role of PARP inhibitors in ovarian cancer, based on data presented for 3 PARP inhibitors, olaparib, rucaparib, and niraparib.


Angelica Welch

Latest:

Expert Discusses Real-World Data for Regorafenib in mCRC

Real-world dosing data for regorafenib in patients with metastatic colorectal cancer was presented at the 2018 ESMO Congress from the prospective, observational CORRELATE study.


Angelica Welsh

Latest:

ADCs Stake Their Claim in Lymphoma Paradigm

Antibody–drug conjugate therapies are making a larger impact on the treatment paradigm for patients with lymphomas, especially following promising data for brentuximab vedotin and inotuzumab ozogamicin.


Angie Kuehl, PharmD

Latest:

Breast Ultrasound Added to Mammography Increases Cancer Detection

More breast cancer lesions were diagnosed in women with dense breasts when ultrasound screening was conducted in conjunction with mammography compared with mammography alone.


Anita Mahajan, MD

Latest:

The Role of Stereotactic Radiosurgery in the Treatment of Brain Metastases

Anita Mahajan, MD, professor, The University of Texas MD Anderson Cancer Center, discusses a recent study into the role of stereotactic radiosurgery in treating brain metastases.


Anita Schaffer

Latest:

First-In-Human Trial Shows Responses With Off-the-Shelf CAR T-Cell Therapy in Myeloma

The off-the-shelf CAR T-cell therapy ALLO-715, which targets BCMA, demonstrated responses as treatment of patients with heavily pretreated relapsed/refractory multiple myeloma in a first-in-human clinical trial.


Anita Shaffer

Latest:

Durable Complete Remissions Achieved in NHL Following CAR T

Complete remissions were achieved in greater than 20% of patients with highly refractory non-Hodgkin lymphomas who had been previously been treated with chimeric antigen receptor T-cell therapy with Mosunetuzumab, a novel bispecific antibody, according to study results presented at the 2019 American Society of Hematology Annual Meeting.


Anita T. Shaffer

Latest:

CASPIAN Update Shows Ongoing Survival Benefit With Durvalumab in ES-SCLC

“Importantly, the separation among the curves seems to be observed over time and, indeed, survival at 2 years improves from 14% [of participants] in the control arm to 22% on the experimental arm. The magnitude of the benefit is very similar and very consistent across all the prespecified subgroups of patients analyzed, including those treated with cisplatin or those patients with liver or brain metastases.”


Ann H. Klopp, MD, PhD

Latest:

Findings of a Study Comparing Standard Radiation to IMRT in Endometrial, Cervical Cancer

Ann H. Klopp, MD, PhD, discusses the results of a recent trial comparing standard radiation to intensity-modulated radiation therapy (IMRT) in endometrial and cervical cancer, and what impact these results will have.


Ann-Lii Cheng, MD

Latest:

Moving Forward From Monotherapy in HCC

Ann-Lii Cheng, MD, discusses where the of hepatocellular carcinoma is headed.


Ann Partridge, MD

Latest:

Dr. Ann Partridge on Aggressive Breast Cancer in Younger Women

Partridge says that the current school of thought is younger women should be treated the same as older women with breast cancer, though younger women tend to develop more aggressive breast cancer with more nodal involvement.


Ann Partridge, MD, MPH

Latest:

Dr. Ann Partridge on Epidemic of Bilateral Mastectomies in Breast Cancer

Partridge says there continues to be a growing epidemic of women getting a bilateral mastectomy for unilateral breast cancer. These surgeries include women who are not at high-risk.


Ann S. LaCasce, MD

Latest:

LaCasce Discusses the Potential Impact of Drug Shortages on Clinical Trials

Ann LaCasce, MD, MMSc, discusses the effects that chemotherapy drug shortages may have on clinical trials and patient accrual.


Ann W. Silk, MD

Latest:

Preliminary Results of Coxsackievirus With Pembrolizumab In Advanced Melanoma

Ann W. Silk, MD, discusses preliminary results of the CAPRA trial, a phase 1B study of intratumoral coxsackievirus A21 (CVA21; CAVATAK) and systemic pembrolizumab in patients with advanced melanoma.


Anna Azvolinsky, PhD

Latest:

Androgen-Targeting Therapies Increasing in CRPC

A new generation of agents that target androgen synthesis and AR signaling have provided proof of concept and robust data to support the hypothesis that the androgen pathway remains an important factor throughout the treatment of CRPC.


Anna C. Pavlick, DO

Latest:

Dr. Pavlick on the Importance of Tumor Biopsies in Melanoma

Anna C. Pavlick, DO, co-director, Melanoma Program, assistant director, Clinical Research Education, associate professor, Departments of Medicine and Dermatology, Langone Medical Center, New York University, discusses the benefits of biopsying melanoma tissue before treatment to better target therapy.


Anna C. Pavlick, MD

Latest:

Ipilimumab Combined With Nivolumab for the Treatment of Patients With Melanoma

Anna C. Pavlick, MD, associate professor, co-director, Melanoma Program, assistant director, Clinical Research Education, discusses a study that examined two immunotherapy agents, ipilimumab and nivolumab, in patients with melanoma.


Anna Farago, MD, PhD

Latest:

Challenges in Treating Small Cell Lung Cancer

Anna Farago, MD, PhD, assistant, medicine, Massachusetts General Hospital, discusses challenges in treating small cell lung cancer.


Anna Sureda, MD, PhD

Latest:

A Study of Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma

Anna Sureda, MD, PhD, Head of the Clinical Hematology Service at the Institut Català d'Oncologia – Hospitalet de Llobregat in Barcelona, discusses the phase III ECHELON-1 study exploring brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma. 


Anne Chiang, MD, PhD

Latest:

Managing PD-L1-Positive NSCLC in the Long-Term

Anne Chiang, MD, PhD, discusses the takeaways from her presentation given at the 18th Annual New York Lung Cancers Symposium.


​Anne Covey, MD

Latest:

Dr. Anne Covey on Locoregional Therapy in Hepatocellular Carcinoma

​Anne Covey, MD, discusses options for patients with hepatocellular carcinoma (HCC) who cannot undergo resection or transplant.


Anne Marie McCarthy, PhD

Latest:

Breast Density in Black Versus White Women

Anne Marie McCarthy, PhD, research fellow, Massachusetts General Hospital, discusses a study that examined breast density, a risk that can help target breast cancer, in black women compared to white women.


Anne S. Tsao, MD

Latest:

Future Targeted Therapy Approaches in NSCLC

Anne S. Tsao, MD, and Edward B. Garon, MD, MS, conclude their discussion with a look to the future of TROP2 and associated targeted therapy approaches in non–small cell lung cancer.